Back to Search
Start Over
[A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
- Source :
-
Zhonghua fu chan ke za zhi [Zhonghua Fu Chan Ke Za Zhi] 2013 May; Vol. 48 (5), pp. 358-63. - Publication Year :
- 2013
-
Abstract
- Objective: To investigate the efficacy of adenosine triphosphate (ATP)-tumor chemosensitivity assay (TCA) directed chemotherapy in patients with recurrent epithelial ovarian cancer.<br />Methods: From August 2010 to June 2012, recurrent epithelial ovarian cancer patients were prospectively enrollmented in Cancer Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences.The entry criteria are as follows: (1) Histologically proven to be epithelial ovarian cancer. (2) Patients of recurrent ovarian cancer with bidimensionally measurable tumor, or ascitic or pleural fluid for testing. (3) Karnofsky performance status > 60. (4) A life expectancy of at least more than 6 months.According to patients desires, they were assigned into two groups: assay-directed therapy group and physician's-choice therapy group, patients' clinical and pathological characteristics, response rate to chemotherapy and progression-free survival (PFS) were compared between two groups.<br />Results: A total of 113 patients with recurrent epithelial ovarian cancer were prospectively enrollmented to assay-directed chemotherapy (n = 56) or physician's-choice chemotherapy (n = 57).There was no difference in median age,types of recurrence, surgical-pathological stage, pathological type, tumor grade, times of recurrence, residual disease at secondary cytoreductive surgery between assay-directed group and physician's-choice group. The overall response rate (ORR) and median PFS in the ATP-TCA group was 66% (37/56) and 7 months, while the ORR in the control group was 46% (26/57, P = 0.037), the median PFS was 4 months (P = 0.040). For platinum-resistant patients, the ORR between ATP-TCA directed chemotherapy 59% (16/27) and control group 25% (7/28) were significantly different (P = 0.010), and the median PFS between two groups were also significantly different (5 months and 2 months, respectively, P = 0.003).<br />Conclusion: ATP-TCA directed chemotherapy could improve ORR and PFS in patients with recurrent epithelial ovarian cancer, especially in platinum-resistant patients.
- Subjects :
- Adenocarcinoma metabolism
Adenocarcinoma mortality
Adenocarcinoma pathology
Adult
Aged
Cisplatin therapeutic use
Disease-Free Survival
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor methods
Female
Humans
Middle Aged
Ovarian Neoplasms metabolism
Ovarian Neoplasms mortality
Ovarian Neoplasms pathology
Paclitaxel therapeutic use
Predictive Value of Tests
Prospective Studies
Sensitivity and Specificity
Survival Rate
Adenocarcinoma drug therapy
Adenosine Triphosphate metabolism
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Neoplasm Recurrence, Local drug therapy
Ovarian Neoplasms drug therapy
Subjects
Details
- Language :
- Chinese
- ISSN :
- 0529-567X
- Volume :
- 48
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Zhonghua fu chan ke za zhi
- Publication Type :
- Academic Journal
- Accession number :
- 24016479